Binimetinib targets which kinases?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $25.99Unlock all

Study for the Pharmacology Presentation Drugs Test. Delve into flashcards and multiple choice questions with hints and explanations. Gear up for examination success!

Multiple Choice

Binimetinib targets which kinases?

Explanation:
Binimetinib is a selective inhibitor of MEK1 and MEK2, two kinases in the MAPK/ERK signaling cascade. By blocking MEK1/2, it prevents the phosphorylation and activation of ERK1/2, which slows or stops the transcription of genes that drive cell proliferation and survival. That’s why MEK1 and MEK2 are the kinases binimetinib targets. The other options refer to kinases in different places or pathways: ERK1/2 are the downstream substrates of MEK1/2, not the drug’s target; RAF1 and BRAF are upstream kinases that activate MEK; and JNK1/2 belong to a separate JNK pathway.

Binimetinib is a selective inhibitor of MEK1 and MEK2, two kinases in the MAPK/ERK signaling cascade. By blocking MEK1/2, it prevents the phosphorylation and activation of ERK1/2, which slows or stops the transcription of genes that drive cell proliferation and survival. That’s why MEK1 and MEK2 are the kinases binimetinib targets. The other options refer to kinases in different places or pathways: ERK1/2 are the downstream substrates of MEK1/2, not the drug’s target; RAF1 and BRAF are upstream kinases that activate MEK; and JNK1/2 belong to a separate JNK pathway.

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy